Scientific Program
Wednesday, September 11, 2024
| 11:30-13:00 |
Pre-Congress Symposium:
AI in breast imaging |
Hall B |
| Chairpersons |
|
| 11:30-11:45 |
Hype or hope: Breast imaging and Artificial Intelligence
Gerald Lip, Aberdeen, Scotland, UK |
| 11:45-12:00 |
Optimizing breast MRI utility with AI
Karla Sepulveda, Houston, TX, USA
|
| 12:00-13:00 |
Round Table Discussion:
James Blackwood, Glenboig, Scotland, UK
Julia Camps Herrero, Valencia, Spain |
| 13:00-13:15 |
Congress Opening |
Hall A |
| Chairpersons |
Leena Chagla, Cheshire, UK
Bruce Mann, Melbourne, Australia |
|
Welcome from Congress chairpersons
|
| 13:15-14:45 |
Session 1: Neoadjuvant therapy |
Hall A |
| Chairpersons |
Leena Chagla, Cheshire, UK
Bruce Mann, Melbourne, Australia |
13:15-13:50
13:15
13:25
13:35 |
Debate: That cT1cN0 HER2+ve should have NAST
Yes: Javier Cortes, Madrid, Spain
No: Sarah Downey, Norfolk, UK
Discussion |
| 13:50-14:05 |
Imaging during NAST
Julia Camps Herrero, Valencia, Spain |
14:05-14:45
14:05
14:15
14:25 |
Debate: Patients with a positive TAD post NACT should have completion axillary clearance
Yes: Stephen Grobmyer, Abu Dhabi, UAE
No: Amit Goyal, Derby, UK
Discussion |
| 14:40-15:10 |
Coffee break, poster viewing and exhibition visit |
| 15:10-16:10 |
Session 2: Imaging |
Hall A |
| Chairpersons |
Nisha Sharma, Leeds, UK
Karla Sepulveda, Houston, TX, USA |
15:10-15:40
15:10
15:20
15:30 |
Debate: The Contrast Breast Imaging should be routine prior to surgery for DCIS or invasive cancer
Yes: Bruce Mann, Melbourne, Australia
No: Stuart McIntosh, Belfast, UK
Discussion |
15:40-16:10
15:40
15:50
16:00 |
Debate: The CEM should be the surveillance imaging test for most patient with past history of breast cancer
Yes: Allison Rose, Melbourne, Australia
No: Sarah Savaridas, Dundee, Scotland, UK
Discussion |
| 15:10-16:10 |
Session 3: HER2+ve disease |
Hall B |
| Chairpersons |
Richard de Boer, Melbourne, Australia
Olga Oikonomidou, Edinburgh, Scotland, UK |
15:10-15:40
15:10
15:20
15:30 |
Debate: Do anthracyclines still have a place in the treatment of early stage HER2+ve BC?
Yes: Richard Simcock, Surrey, UK
No: Kevin Kalinsky, Atlanta, GA, USA
Discussion |
| 15:40-15:55 |
HER2 low
Sarah Pinder, London, UK |
| 15:55-16:10 |
Is there a threshold for systemic treatment of HER2+ve cancer?
Iain MacPherson, Glasgow, Scotland, UK
|
| 16:10-17:10 |
Session 4: DCIS |
Hall A |
| Chairpersons |
Bruce Mann, Melbourne, Australia
Tracey Irvine, Surrey, UK |
16:10-16:40
16:10
16:20
16:30 |
Debate: That most patients with DCIS should have radiotherapy after Breast Conserving Surgery
Yes: Frank A. Vicini, Farmington Hillis, MI, USA
No: Elinor Sawyer, London, UK
Discussion |
16:40-17:10
16:40
16:50
17:00 |
Debate: That active surveillance for low risk DCIS is a reasonable option
Yes: Shelley Potter, Bristol, UK
No: Henry J. Cain, Newcastle upon Tyne, UK
Discussion |
| 16:10-17:10 |
Session 5: Metastatic HR+ve breast cancer
|
Hall B |
| Chairpersons |
Richard de Boer, Melbourne, Australia
Olga Oikonomidou, Edinburgh, Scotland, UK
|
| 16:10-16:40 |
What to do after progression on CDKi
Kevin Kalinsky, Atlanta, GA, USA |
16:40-17:10
16:40
16:50
17:00 |
Debate: That CDKi should be first line treatment for ~all HR+ve MBC
Yes: Javier Cortes, Madrid, Spain
No: Mark Verrill, Newcastle upon Tyne, UK
Discussion |
| 17:15-18:15 |
Networking Reception |
Thursday, September 12, 2024
| 08:30-09:30 |
Session 6: Breast cancer in young women |
Hall A |
| Chairpersons |
Ramsey Cutress, Southampton, UK
Yazan Masannat, Essex, UK |
| 08:30-09:00 |
Controversies in breast cancer management in young women
Ann Partridge, Boston, MA, USA |
09:00-09:30
09:00
09:10
09:20 |
Debate: That women <35 with breast cancer should be advised to have bilateral total mastectomy
Yes: Michael Alvarado, San Francisco, CA, USA
No: J. Michael Dixon, Edinburgh, Scotland, UK
Discussion |
| 09:30-11:00 |
Session 7: Screening |
Hall A |
| Chairpersons |
Sarah Downey, Norfolk, UK
Laszlo Romics, Glasgow, Scotland, UK
|
09:30-10:00
09:30
09:40
09:50 |
Debate: That a change to risk-adjusted screening is urgent and feasible
Yes: D. Gareth Evans, Manchester, UK
No: Cliona Kirwan, Manchester, UK
Discussion |
| 10:00-10:25 |
CBI in screening
Allison Rose, Melbourne, Australia |
10:25-11:00
10:25
10:35
10:45 |
Debate: That women at low risk for breast cancer should only be screened every 5 years
Yes: Nisha Sharma, Leeds, UK
No: Karla Sepulveda, Houston, TX, USA
Discussion |
| 09:30-11:00 |
Session 8: Triple negative breast cancer |
Hall B |
| Chairpersons |
Richard de Boer, Melbourne, Australia
Richard Simcock, Surrey, UK
|
09:30-10:00
09:30
09:45
10:00 |
Debate: That all stage 2/3 TNBC patients should be treated according to Keynote522 regimen
Yes: Olga Oikonomidou, Edinburgh, Scotland, UK
No: Carlo Palmieri, Liverpool, UK
Discussion |
| 10:10-10:25 |
TNBC subtypes: Do they have clinical significance?
Matthew J. Ellis, Houston, TX, USA |
10:25-11:00
10:25
10:35
10:45 |
Debate: Asymptomatic patients with high-risk TNBC should undergo surveillance imaging
Yes: Ann Partridge, Boston, MA, USA
No: Alistair Ring, London, UK
Discussion |
| 11:00-11:30 |
Coffee break, poster viewing and exhibition visit |
| 11:30-12:30 |
Session 9: Metastatic Breast Cancer |
Hall A |
| Chairpersons |
Olga Oikonomidou, Edinburgh, Scotland, UK
Iain MacPherson, Glasgow, Scotland, UK |
11:30-12:00
11:30
11:40
11:50 |
Debate: That molecular testing of tumours should be routine for patients with metastatic breast cancer
Yes: Marina Parton, London, UK
No: Richard de Boer, Melbourne, Australia
Discussion |
12:00-12:30
12:00
12:10
12:20 |
Debate: SABR should be considered in most patients with oligometastatic breast cancer
Yes: John Conibear, London, UK
No: Stephen Harrow, Edinburgh, Scotland, UK
Discussion |
| 11:30-12:30 |
Session 10: Free Papers |
Hall B |
| Chairpersons |
Lynda Wyld, Sheffield, UK
Raghavan Vidya, Birmingham, UK |
| 11:30-11:40 |
Variation in practice and provision of contralateral symmetrising mastectomy after unilateral mastectomy for breast cancer: A UK national practice survey
Katherine Fairhurst, Bristol, UK |
| 11:40-11:50 |
Mammographic surveillance in early breast cancer patients aged 50 years or over: Results of the Mammo-50 non-inferiority trial of annual versus less frequent mammography
Janet Dunn, Coventry, UK |
11:50-12:00
|
Oncoplastic breast conservation surgery increases survival in comparison to mastectomy in a west of Scotland population-based study with long-term follow-up
Mhairi Mactier, Clydebank, Scotland, UK |
12:00-12:10
|
Uptake of breast cancer screening with mammography and ultrasound in China: A multi-centre population-based study
Yadi Zheng, China |
| 12:10-12:20 |
Cumulative risk of cosmetic worsening following ultra-hypofractionated whole breast radiotherapy with simultaneous integrated boost: Largest real-world data
Tabassum Wadasadawala, Mumbai, India |
| 12:20-12:30 |
Factors influencing immediate reconstruction and complications for gene carriers in those undergoing mastectomy in KConFAb population
Anita Skandarajah, Melbourne, Australia |
| 13:30-14:30 |
Lunch break, poster viewing and exhibition visit |
| 14:30-15:30 |
Session 11: Genetics |
Hall A |
| Chairpersons |
Alastair Thompson, Houston, TX, USA
Douglas Ferguson, Exeter, UK |
14:30-15:00
14:30
14:40
14:50 |
Debate: That most cancer patients with gene mutations should be offered breast conservation
Yes: D. Gareth Evans, Manchester, UK
No: Stuart McIntosh, Belfast, UK
Discussion |
| 15:00-15:15 |
The ‘new genes’: What do they mean for patients and families?
Jennie Murray, Edinburgh, Scotland, UK |
| 15:15-15:30 |
What is the appropriate timing of risk reduction BSO in BRCA patients?
Cameron Martin, Edinburgh, Scotland, UK |
| 14:30-15:30 |
Session 12: Free Papers |
Hall B |
| Chairpersons |
|
| 14:30-14:40 |
Verification of the BCAL diagnostics novel lipidomics-based liquid biopsy test BREASTEST for the detection of early-stage breast cancer in an Australian population
David Speakman, Melbourne, Australia |
| 14:40-14:50 |
Pathological complete response rate in neoadjuvant chemotherapy versus concurrent chemo-endocrine therapy in hormone receptor positive, HER2 negative breast cancer
Shalaka Joshi, Mumbai, India |
14:50-15:00
|
Why have health technology assessment boards reached differing conclusions about the ability of tumour gene expression tests to predict chemotherapy benefit for postmenopausal breast cancer patients?
Robert Stein, London, UK |
15:00-15:10
|
A morphometric signature for HER2 activity predicts recurrence risk in breast cancer
Nehal Atallah, Nottingham, UK |
| 15:10-15:20 |
Something old, new or borrowed: Optimum second line therapy after CDK4-6 inhibition
Andrew Redfern, Murdoch, Australia |
| 15:20-15:30 |
Identifying oestrogen receptor-related genes of predictive value in breast cancer
Shorouk Makhlouf, Nottingham, UK |
| 15:30-16:00 |
Coffee break, poster viewing and exhibition visit |
| 16:00-17:30 |
Session 13: Adjuvant endocrine therapy |
Hall A |
| Chairpersons |
Cliona Kirwan, Manchester, UK
John Benson, Cambridge, UK |
| 16:00-16:45 |
Why my assay is best |
| 16:00 |
PAM 50
Matthew J. Ellis, Houston, TX, USA |
| 16:15 |
ODX
Kevin Kalinsky, Atlanta, GA, USA |
16:30
|
Mammaprint
William Audeh, Los Angeles, CA, USA |
16:45-17:30
16:45
17:00
17:15 |
Debate: That adjuvant CDKs should be recommended for intermediate risk ER+HER2-EBC
Yes: Kevin Kalinsky, Atlanta, GA, USA
No: Alistair Ring, London, UK
Discussion |
Friday, September 13, 2024
| 08:30-10:00 |
Session 14: Reconstruction |
Hall A |
| Chairpersons |
Leena Chagla, Cheshire, UK
Krishna Clough, Paris, France
|
| 08:30-09:00 |
Fat grafting, realistic expectations and long-term results
Krishna Clough, Paris, France |
| 09:00-10:00 |
MDT Round Table Discussion on tricky oncoplastic/reconstructive topics
Case presenters:
Rajiv Dave, Manchester, UK
Kenneth Elder, Edinburgh, Scotland, UKPanel:
J. Michael Dixon, Edinburgh, Scotland, UK
Adam Gilmour, Glasgow, Scotland, UK
Andrew Malyon, Glasgow, Scotland, UK
James Mansell, Glasgow, Scotland, UK
Lynda Wyld, Sheffield, UK
|
| 08:30-10:00 |
Session 15: Supportive care |
Hall B |
| Chairpersons |
Olga Oikonomidou, Edinburgh, Scotland, UK
Katy Ellis, Manchester, UK |
| 08:30-09:00 |
TBA
Lesley Fallowfield, Sussex, UK |
| 09:00-09:30 |
Symptoms of menopause and how to manage them following breast cancer
Paula Briggs, Liverpool, UK |
| 09:30-10:00 |
TBA
Marina Parton, London, UK |
| 10:00-10:30 |
Coffee break, poster viewing and exhibition visit |
| 10:30-11:30 |
Session 16: Locoregional management |
Hall A |
| Chairpersons |
Krishna Clough, Paris, France
Stephen Grobmyer, Abu Dhabi, UAE |
10:30-11:00
10:30
10:40
10:50 |
Debate: That patients with heavy axillary nodal disease pre-NACT should have axillary dissection irrespective of response to NACT
Yes: Alastair Thompson, Houston, TX, USA
No: Leena Chagla, Cheshire, UK
Discussion |
11:00-11:30
11:00
11:10
11:20 |
Debate: That all patients with 1-3 macrometastases in axillary nodes should have Regional Nodal Radiation
Yes: Elinor Sawyer, London, UK
No: Michael Douek, London, UK
Discussion |
| 11:30-12:30 |
Session 17: Breast Cancer 2035 |
Hall A |
| Chairpersons |
Leena Chagla,Cheshire, UK
Bruce Mann, Melbourne, Australia |
| 11:30-11:45 |
Oncoplastic surgery in 2035
Krishna Clough, Paris, France |
| 11:45-12:00 |
Early detection in 2035
Karla Sepulveda, Houston, TX, USA |
| 12:00-12:15 |
Management of Stage 1 breast cancer in 2035
Bruce Mann, Melbourne, Australia |
| 12:15-12:30 |
Systemic therapy in 2035
Olga Oikonomidou, Edinburgh, Scotland, UK |
| 12:30-12:45 |
Congress closing and Award presentation |
Hall A |
| Chairpersons |
Leena Chagla, Cheshire, UK
Bruce Mann, Melbourne, Australia
|
- Program is subject to change
